A Phase I/II Study of Brigatinib in Pediatric and Young Adult Patients With ALK+ Anaplastic Large Cell Lymphoma, Inflammatory Myofibroblastic Tumors or Other Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 12 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Brigatinib (Primary)
Indications Anaplastic large cell lymphoma; Muscle tissue neoplasms; Sarcoma; Solid tumours
Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
Acronyms Briga-PED

04 Jun 2024 Results (n=10) of a pediatric phase 1 study in patients (pts) with ALK+ malignancies presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
24 Mar 2023 Results using body weight bins data in NCT04925609, to support support a brigatinib dosing approach , presented at the 124th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
15 Aug 2022 Planned initiation date (estimated date for recruitment of the first subject) changed from 1 May 2022 to 31 Aug 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com